Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Ankit J Kansagra; Noelle V Frey; Merav Bar; Theodore W Laetsch; Paul A Carpenter; Bipin N Savani; Helen E Heslop; Catherine M Bollard; Krishna V Komanduri; Dennis A Gastineau; Christian Chabannon; Miguel A Perales; Michael Hudecek; Mahmoud Aljurf; Leslie Andritsos; John A Barrett; Veronika Bachanova; Chiara Bonini; Armin Ghobadi; Saar I Gill; Joshua A Hill; Saad Kenderian; Partow Kebriaei; Arnon Nagler; David Maloney; Hien D Liu; Nirali N Shah; Mohamed A Kharfan-Dabaja; Elizabeth J Shpall; Ghulam J Mufti; Laura Johnston; Elad Jacoby; Ali Bazarbachi; John F DiPersio; Steven Z Pavletic; David L Porter; Stephan A Grupp; Michel Sadelain; Mark R Litzow; Mohamad Mohty; Shahrukh K Hashmi

doi:10.1038/s41409-019-0451-2

Back

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Journal article

Open access

Peer reviewed

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Ankit J Kansagra, Noelle V Frey, Merav Bar, Theodore W Laetsch, Paul A Carpenter, Bipin N Savani, Helen E Heslop, Catherine M Bollard, Krishna V Komanduri, Dennis A Gastineau, …

Bone marrow transplantation (Basingstoke), Vol.54(11), pp.1868-1880

2019-05-15

DOI: https://doi.org/10.1038/s41409-019-0451-2

PMID: 31092900

Abstract

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Files and links (1)

url

https://doi.org/10.1038/s41409-019-0451-2View

Published (Version of record) Open

Metrics

9 Record Views

52 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.6 Immunology; 1.6.214 PD-1
Web Of Science research areas: Biophysics; Hematology; Immunology; Oncology; Transplantation
ESI research areas: Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Creators: Ankit J Kansagra - Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Noelle V Frey - Cell Therapy and Transplant Program, Abramson Cancer Center and the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Merav Bar - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Theodore W Laetsch - Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Health, Dallas, TX, USA
Paul A Carpenter - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Bipin N Savani - Division of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
Helen E Heslop - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA
Catherine M Bollard - Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA
Krishna V Komanduri - Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA
Dennis A Gastineau - Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, USA
Christian Chabannon - Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT, 1409, Marseille, France
Miguel A Perales - Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Michael Hudecek - Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
Mahmoud Aljurf - Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Leslie Andritsos - Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA
John A Barrett - Stem Cell Transplantation and Cellular Therapy Program, GW Cancer Center, George Washington University, Washington, DC, USA
Veronika Bachanova - Division of Hematology/Oncology/Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA
Chiara Bonini - Experimental Hematology Unit, University Vita-Salute San Raffaele and Ospedale San Raffaele, Milano, Italy
Armin Ghobadi - Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
Saar I Gill - Cell Therapy and Transplant Program, Abramson Cancer Center and the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Joshua A Hill - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Saad Kenderian - Department of Immunology, Mayo Clinic, Rochester, MN, USA
Partow Kebriaei - Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Arnon Nagler - The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
David Maloney - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Hien D Liu - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Nirali N Shah - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Mohamed A Kharfan-Dabaja - Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA
Elizabeth J Shpall - The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Ghulam J Mufti - Department of Haematological Medicine, King's College, London, UK
Laura Johnston - Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
Elad Jacoby - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Ali Bazarbachi - Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
John F DiPersio - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Steven Z Pavletic - Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
David L Porter - Cell Therapy and Transplant Program, Abramson Cancer Center and the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
Stephan A Grupp - Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
Michel Sadelain - Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, New York, NY, USA
Mark R Litzow - Department of Immunology, Mayo Clinic, Rochester, MN, USA. litzow.mark@mayo.edu
Mohamad Mohty - Hôpital Saint-Antoine, APHP, Sorbonne Universite, INSERM UMRs 938, Paris, France. Mohamed.mohty@inserm.fr
Shahrukh K Hashmi - Department of Immunology, Mayo Clinic, Rochester, MN, USA. hashmi.shahrukh@mayo.edu
Publication Details: Bone marrow transplantation (Basingstoke), Vol.54(11), pp.1868-1880
Publisher: England
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 31092900
Record Identifier: 991031578532602976